{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:41:55Z","timestamp":1787236915090,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prediabetes represents the final stage on the glycemic spectrum before the onset of type 2 diabetes mellitus (T2DM), and delaying its progression offers a unique opportunity to address the growing T2DM epidemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this longitudinal cohort study, we investigated the effect of daily low-dose aspirin on the development of T2DM in individuals with prediabetes residing in Naples, Italy, who were followed by their primary care physicians between 2018 and 2022. Outcomes in the aspirin-treated group were compared with those in a control group not receiving aspirin, using data from the same database. Propensity score matching was employed to ensure comparability of covariates at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The primary outcome was the onset of T2DM, defined as a new diagnosis accompanied by antidiabetic prescriptions lasting more than 30\u00a0days. Gastrointestinal bleeding was assessed as the safety endpoint. Over the follow-up period, 488 new cases of T2DM were documented (15.6% of the total population), with 174 cases occurring in the aspirin group (22.3 per 1000 person-years) and 314 in the non-aspirin group (40.2 per 1000 person-years), indicating a significantly lower incidence of diabetes among aspirin-treated individuals. Given the difference in comorbidity rates between groups, a Cox regression analysis was conducted across the entire follow-up period, showing that aspirin use was associated with a 47% reduction in the risk of developing T2DM (HR 0.53, 95% CI 0.44\u20130.64,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, aspirin use was also linked to an increased risk of gastrointestinal bleeding (4.9% vs 3.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Kaplan\u2013Meier survival curves confirmed a significantly lower cumulative incidence of T2DM in the aspirin-treated group (log-rank test\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Daily treatment with 100\u00a0mg aspirin was associated with approximately a 50% reduction in the incidence of new-onset T2DM, but also with an increased risk of gastrointestinal bleeding, in elderly individuals with prediabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-025-02802-9","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:34:01Z","timestamp":1750228441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Daily low dose aspirin halves incident type 2 diabetes in elderly subjects with prediabetes: a five-year longitudinal cohort study in a real-word population"],"prefix":"10.1186","volume":"24","author":[{"given":"Maria","family":"Lembo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Trimarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pacella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Virginia","family":"Manzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislovas S.","family":"Jankauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Piccinocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Morisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Piccinocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Santulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Trimarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2802_CR1","doi-asserted-by":"crossref","unstructured":"The Lancet Diabetes E. Prediabetes: much more than just a risk factor. Lancet Diabetes Endocrinol 2025;13(3):165.","DOI":"10.1016\/S2213-8587(25)00034-8"},{"issue":"1","key":"2802_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12933-024-02218-x","volume":"23","author":"G Santulli","year":"2024","unstructured":"Santulli G, Visco V, Ciccarelli M, Ferrante MNV, De Masi P, Pansini A, Virtuoso N, Pirone A, Guerra G, Verri V, et al. Frail hypertensive older adults with prediabetes and chronic kidney disease: insights on organ damage and cognitive performance\u2014preliminary results from the CARYATID study. Cardiovasc Diabetol. 2024;23(1):125.","journal-title":"Cardiovasc Diabetol"},{"key":"2802_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2297","volume":"370","author":"X Cai","year":"2020","unstructured":"Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, Yang Y, Hu Y, Huang Y. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370: m2297.","journal-title":"BMJ"},{"issue":"4","key":"2802_CR4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.amjmed.2008.09.044","volume":"122","author":"Y Hayashino","year":"2009","unstructured":"Hayashino Y, Hennekens CH, Kurth T. Aspirin use and risk of type 2 diabetes in apparently healthy men. Am J Med. 2009;122(4):374\u20139.","journal-title":"Am J Med"},{"issue":"2","key":"2802_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S2213-8587(23)00327-3","volume":"12","author":"S Zoungas","year":"2024","unstructured":"Zoungas S, Zhou Z, Owen AJ, Curtis AJ, Espinoza SE, Ernst ME, Woods RL, Orchard SG, McNeil JJ, Murray AM, et al. Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2024;12(2):98\u2013106.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"2802_CR6","doi-asserted-by":"publisher","first-page":"e183777","DOI":"10.1172\/JCI183777","volume":"134","author":"V Trimarco","year":"2024","unstructured":"Trimarco V, Izzo R, Jankauskas SS, Fordellone M, Signoriello G, Manzi MV, Lembo M, Gallo P, Esposito G, Piccinocchi R, et al. A six-year study in a real-world population reveals an increased incidence of dyslipidemia during COVID-19. J Clin Invest. 2024;134(21):e183777.","journal-title":"J Clin Invest"},{"key":"2802_CR7","doi-asserted-by":"crossref","unstructured":"American Diabetes A: 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 2021;44(Suppl 1):S15\u2013S33.","DOI":"10.2337\/dc21-S002"},{"issue":"7","key":"2802_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KG Alberti","year":"1998","unstructured":"Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539\u201353.","journal-title":"Diabet Med"},{"key":"2802_CR9","doi-asserted-by":"crossref","unstructured":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20(7):1183\u20131197.","DOI":"10.2337\/diacare.20.7.1183"},{"issue":"5","key":"2802_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S2213-8587(22)00044-4","volume":"10","author":"Y Xie","year":"2022","unstructured":"Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311\u201321.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2802_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102345","volume":"66","author":"R Izzo","year":"2023","unstructured":"Izzo R, Pacella D, Trimarco V, Manzi MV, Lombardi A, Piccinocchi R, Gallo P, Esposito G, Lembo M, Piccinocchi G, et al. Incidence of type 2 diabetes before and during the COVID-19 pandemic in Naples, Italy: a longitudinal cohort study. EClinicalMedicine. 2023;66: 102345.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"2802_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"Gusto Investigators","year":"1993","unstructured":"Gusto Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673\u201382.","journal-title":"N Engl J Med"},{"issue":"2","key":"2802_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2337\/dc22-0783","volume":"46","author":"P Mone","year":"2023","unstructured":"Mone P, Lombardi A, Salemme L, Cioppa A, Popusoi G, Varzideh F, Pansini A, Jankauskas SS, Forzano I, Avvisato R, et al. Stress hyperglycemia drives the risk of hospitalization for chest pain in patients with ischemia and nonobstructive coronary arteries (INOCA). Diabetes Care. 2023;46(2):450\u20134.","journal-title":"Diabetes Care"},{"issue":"8","key":"2802_CR14","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, Santulli G. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79(8):1633\u201343.","journal-title":"Hypertension"},{"issue":"Suppl 3","key":"2802_CR15","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1038\/sj.ijo.0802501","volume":"27","author":"SE Shoelson","year":"2003","unstructured":"Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta\/I kappa B\/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S49-52.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"3","key":"2802_CR16","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.4049\/jimmunol.0900477","volume":"183","author":"T Morris","year":"2009","unstructured":"Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, Bellingan G, Gilroy DW. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol. 2009;183(3):2089\u201396.","journal-title":"J Immunol"},{"issue":"6","key":"2802_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4158\/EP12064.OR","volume":"18","author":"E Faghihimani","year":"2012","unstructured":"Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes. Endocr Pract. 2012;18(6):826\u201333.","journal-title":"Endocr Pract"},{"issue":"2","key":"2802_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2337\/dc07-1338","volume":"31","author":"A Fleischman","year":"2008","unstructured":"Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289\u201394.","journal-title":"Diabetes Care"},{"issue":"4","key":"2802_CR19","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00125-012-2819-3","volume":"56","author":"AB Goldfine","year":"2013","unstructured":"Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, Shoelson SE, Reaven PD. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013;56(4):714\u201323.","journal-title":"Diabetologia"},{"issue":"1","key":"2802_CR20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12933-024-02525-3","volume":"23","author":"KM Pencina","year":"2024","unstructured":"Pencina KM, Thanassoulis G, Pencina MJ, Toth PP, Sniderman AD. Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study. Cardiovasc Diabetol. 2024;23(1):448.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2802_CR21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1161\/HYPERTENSIONAHA.124.23087","volume":"81","author":"G Santulli","year":"2024","unstructured":"Santulli G, Visco V, Varzideh F, Guerra G, Kansakar U, Gasperi M, Marro A, Wilson S, Ferrante MNV, Pansini A, et al. Prediabetes increases the risk of frailty in prefrail older adults with hypertension: beneficial effects of metformin. Hypertension. 2024;81(7):1637\u201343.","journal-title":"Hypertension"},{"issue":"2","key":"2802_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00125-024-06315-0","volume":"68","author":"MR Rooney","year":"2025","unstructured":"Rooney MR, Wallace AS, Echouffo Tcheugui JB, Fang M, Hu J, Lutsey PL, Grams ME, Coresh J, Selvin E. Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes. Diabetologia. 2025;68(2):357\u201366.","journal-title":"Diabetologia"},{"key":"2802_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118619","volume":"399","author":"P Mone","year":"2024","unstructured":"Mone P, D\u2019Onofrio F, Dazzetti T, De Oliveira Roza TL, Guerra G, Santulli G. Age drives the impact of vascular disease on ischemic stroke in patients with atrial fibrillation: role of hypertension and prediabetes. Atherosclerosis. 2024;399: 118619.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2802_CR24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2337\/dc23-1864","volume":"47","author":"M Al Rifai","year":"2024","unstructured":"Al Rifai M, Al-Mallah MH, Blaha MJ, Patel J, McEvoy JW, Nasir K, Shahid I, Patel KV, Sharma G, Marrugat J, et al. Epidemiology and prognostic implications of coronary artery calcium in asymptomatic individuals with prediabetes: a multicohort study. Diabetes Care. 2024;47(4):698\u2013706.","journal-title":"Diabetes Care"},{"issue":"3","key":"2802_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277\u201387.","journal-title":"JAMA"},{"issue":"11","key":"2802_CR26","first-page":"e563","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563\u201395.","journal-title":"Circulation"},{"key":"2802_CR27","doi-asserted-by":"crossref","unstructured":"Force USPST, Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaen CR et al. Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement. JAMA 2022;327(16):1577\u20131584.","DOI":"10.1001\/jama.2022.4983"},{"issue":"16","key":"2802_CR28","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jama.2022.3385","volume":"327","author":"SP Dehmer","year":"2022","unstructured":"Dehmer SP, O\u2019Keefe LR, Evans CV, Guirguis-Blake JM, Perdue LA, Maciosek MV. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated modeling study for the US preventive services task force. JAMA. 2022;327(16):1598\u2013607.","journal-title":"JAMA"},{"issue":"16","key":"2802_CR29","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.2022.3337","volume":"327","author":"JM Guirguis-Blake","year":"2022","unstructured":"Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the us preventive services task force. JAMA. 2022;327(16):1585\u201397.","journal-title":"JAMA"},{"issue":"9","key":"2802_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.123.065420","volume":"149","author":"R Campbell","year":"2024","unstructured":"Campbell R, Nelson MR, McNeill JJ, McEvoy JW. Outcomes after aspirin discontinuation among baseline users in contemporary primary prevention aspirin trials: a meta-analysis. Circulation. 2024;149(9):722\u20134.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02802-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02802-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02802-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:24:10Z","timestamp":1781605450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-02802-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2802"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02802-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adhering to the \u2018Strengthening the Reporting of Observational Studies in Epidemiology\u2019 (STROBE) reporting guidelines, this cohort study received approval from the Ethics Board at the \u201cASL Napoli 1 Centro,\u201d with a waiver of informed consent granted in view of the anonymized collection of data (Protocol #257\/22\u20132023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. G. Santulli serves as Associate Editor of Cardiovascular Diabetology; however, he did not participate in any way in handling this manuscript. The other authors declare that they have no competing financial interests that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"259"}}